Journal article
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis
Abstract
BackgroundTP53 mutations, which are present in 5% to 10% of patients with acute myeloid leukemia (AML), are associated with treatment resistance and poor outcomes. First-line therapies for TP53-mutated (TP53m) AML consist of intensive chemotherapy (IC), hypomethylating agents (HMA), or venetoclax combined with HMA (VEN + HMA).MethodsWe conducted a systematic review and meta-analysis to describe and compare treatment outcomes in newly diagnosed …
Authors
Daver NG; Iqbal S; Renard C; Chan RJ; Hasegawa K; Hu H; Tse P; Yan J; Zoratti MJ; Xie F
Journal
Journal of Hematology & Oncology, Vol. 16, No. 1,
Publisher
Springer Nature
DOI
10.1186/s13045-023-01417-5
ISSN
1756-8722